Stocktoria
IMPACT BIOMEDICAL INC. IBO
IMPACT BIOMEDICAL INC. (IBO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $32,000 at a -36993.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.043 |
| Retained earnings / assets | -2.844 |
| EBIT / assets | -0.246 |
| Equity / liabilities | 8.408 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | 2/9 | — | — | — |
About IMPACT BIOMEDICAL INC.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc
FAQ
Is IBO financially healthy?
IMPACT BIOMEDICAL INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IBO pay a dividend?
No, IMPACT BIOMEDICAL INC. does not currently pay a dividend.
How profitable is IBO?
In FY2025, IMPACT BIOMEDICAL INC. had a net margin of -36993.8% and a return on equity of -76.1%.
Is IBO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IMPACT BIOMEDICAL INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.